Natriuretic Peptide Or Derivative (e.g., Atrial Natriuretic Peptide, Brain Natriuretic Peptide, Etc.) Patents (Class 514/12.4)
  • Patent number: 11105819
    Abstract: Disclosed is a composition that synergistically prevents proteolysis or modification of peptides in sampled biological fluids using sulfonyl fluoride family protease inhibitors at high concentrations combined with at least one additional protease inhibitor of a different type, preferably a broad spectrum protease inhibitor, and a chelator. A preferred embodiment uses AEBSF at 10 mM, Benzamidine at 20 mM and EDTA as the chelator. The disclosed composition may be combined with other protease inhibitors to further modulate its specificity, for instance to additionally target acidic proteases. Additional protease inhibitors, reducing agents, stabilizers and buffering agents may be combined with the disclosed compositions in devices for sampling or testing biological fluids for levels of peptides of interest, or methods therefore. The disclosed devices, compositions and methods are of particular use in sampling and testing for the level of natriuretic peptides.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: August 31, 2021
    Assignee: CRIMSON U.S. ASSETS LLC
    Inventors: Ute Schellenberger, Eric E. Niederkofier, Urban A. Kiernan, Jessica O'Rear, Randall W. Nelson
  • Patent number: 10641781
    Abstract: Disclosed is a composition that synergistically prevents proteolysis or modification of peptides in sampled biological fluids using sulfonyl fluoride family protease inhibitors at high concentrations combined with at least one additional protease inhibitor of a different type, preferably a broad spectrum protease inhibitor, and a chelator. A preferred embodiment uses AEBSF at 10 mM, Benzamidine at 20 mM and EDTA as the chelator. The disclosed composition may be combined with other protease inhibitors to further modulate its specificity, for instance to additionally target acidic proteases. Additional protease inhibitors, reducing agents, stabilizers and buffering agents may be combined with the disclosed compositions in devices for sampling or testing biological fluids for levels of peptides of interest, or methods therefore. The disclosed devices, compositions and methods are of particular use in sampling and testing for the level of natriuretic peptides.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: May 5, 2020
    Assignee: CRIMSON U.S. ASSETS LLC
    Inventors: Ute Schellenberger, Eric E. Niederkofier, Urban A. Kiernan, Jessica O'Rear, Randall W. Nelson
  • Patent number: 9907834
    Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: March 6, 2018
    Assignee: BioMarin Pharmaceutical Inc.
    Inventors: Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O. Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap
  • Patent number: 9764002
    Abstract: Disclosed herein is the use of an active agent comprising a peptide derived from atrial natriuretic peptide (ANP) prohormone or a mimetic thereof in the manufacture of a medicament for treating a disease in a subject. The medicament is administered subcutaneously in a multimodal dosage regime comprising at least an initial dosage stage and at least one maintenance dosage stage. The initial dosage stage comprises infusing the active agent at an initial dosage rate for an initial period to achieve a target steady state blood plasma concentration of the active agent or metabolite thereof. The maintenance dosage stage(s) comprise(s) adjusting the dosage rate to a maintenance dosage rate for a maintenance period to substantially maintain said target steady state blood plasma concentration of the active agent or metabolite thereof.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: September 19, 2017
    Assignee: MADELEINE PHARMACEUTICALS PTY LTD
    Inventors: Thomas Robert Geimer, Richard Neil Upton
  • Patent number: 9126956
    Abstract: In one aspect, the invention relates to compounds having the formula: where X, Ra, Rb, R2, and R7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: September 8, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Melissa Fleury, Adam D. Hughes
  • Patent number: 9108934
    Abstract: In one aspect, the invention relates to compounds having the formula XII: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: August 18, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Adam D. Hughes, Melissa Fleury
  • Publication number: 20150125457
    Abstract: The present invention provides a bone repair promoter containing as an active ingredient at least one kind of B-type natriuretic peptide receptor agonist.
    Type: Application
    Filed: October 24, 2014
    Publication date: May 7, 2015
    Inventors: Naomi WAKABAYASHI, Akira YAMAKI, Masako SUGIYAMA
  • Patent number: 9023794
    Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: May 5, 2015
    Assignee: Cardiorentis AG
    Inventors: Veselin Mitrovic, Hartmut Luss, Wolf-Georg Forssmann, Markus Meyer, Klaus Dohler
  • Publication number: 20150080844
    Abstract: Intradermal delivery devices, systems and methods thereof for the administration of a natriuretic or chimeric peptide are described. The described delivery devices, systems and methods provide for the treatment of pathological conditions such as kidney disease alone, heart failure alone, concomitant kidney disease and heart failure, or cardiorenal syndrome by delivery of a natriuretic or chimeric peptide through a microneedle array using a delivery pump. The described delivery devices, systems and methods can provide for greater availability of a natriuretic or chimeric peptide and improved pharmacokinetics.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 19, 2015
    Applicant: Medtronic, Inc.
    Inventors: Maura Donovan, William J. L. van Antwerp, Chad A. Wieneke, Mike Kaytor, Eric Grovender
  • Publication number: 20150045301
    Abstract: The invention provides NP compounds such as proteins, peptides, peptidomimetics, derivatives and analogs for treating retinal disorders and diseases.
    Type: Application
    Filed: December 17, 2012
    Publication date: February 12, 2015
    Inventor: Michael Kozlowski
  • Publication number: 20150038418
    Abstract: Therapeutic compositions containing natriuretic peptides for treating chronic kidney disease alone, heart failure alone, or chronic kidney disease with concomitant heart failure are described. The therapeutic compositions have enhanced stability characteristics to facilitate storage and delivery by provisioning apparatuses under conditions of elevated temperature and mechanical stress. Methods for increasing the stability of therapeutic compositions containing natriuretic peptides are further described.
    Type: Application
    Filed: July 19, 2012
    Publication date: February 5, 2015
    Applicant: MEDTRONIC, INC.
    Inventors: William Van Antwerp, Dianne Judd, Andrew Walsh, Lian Luo
  • Publication number: 20150018276
    Abstract: A method of treating cancer through use of guanosine 3?,5?-cyclic monophosphate (cyclic GMP). Cyclic GMP decreases the number of human breast cancer and prostate adenocarcinoma as well as small-cell and squamous lung cells in culture by 30% (1 ?M), 84% (1 mM), 31% (1 ?M), and 30% (1 ?M), respectively. Cyclic GMP decreases DNA synthesis in human pancreatic, breast, and prostate adenocarcinomas as well as small-cell and squamous cell carcinomas of the lung at its 1 ?M concentration by 51%, 54%, 56%, 50% and 52%, respectively. Cyclic GMP when infused for one week decreases the tumor volume of human pancreatic adenocarcinomas in athymic mice 95% compared to untreated animals with human pancreatic adenocarcinomas.
    Type: Application
    Filed: June 20, 2014
    Publication date: January 15, 2015
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventor: DAVID L. VESELY
  • Patent number: 8912137
    Abstract: Methods and materials for diagnosing and treating heart conditions (e.g., heart failure) and kidney conditions (e.g., kidney failure) are described.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: December 16, 2014
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Shuchong Pan, Robert D. Simari
  • Publication number: 20140357561
    Abstract: This document provides natriuretic polypeptide delivery systems. For example, methods and materials related to natriuretic polypeptide delivery systems, methods and materials related to the use of such delivery systems to deliver natriuretic polypeptides to a mammal over a pro-longed period of time (e.g., weeks to months), and methods and materials related to treating heart failure conditions are provided.
    Type: Application
    Filed: July 24, 2014
    Publication date: December 4, 2014
    Inventors: Horng H. Chen, John C. Burnett, JR., Lim Soo Ghim, Subramanian K. Venkatraman
  • Publication number: 20140357562
    Abstract: This application describes a family of compounds acting as ?-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.
    Type: Application
    Filed: August 15, 2014
    Publication date: December 4, 2014
    Inventors: Dennis Yamashita, Xiao-Tao Chen
  • Publication number: 20140323402
    Abstract: The present invention relates to water-soluble protein carrier-linked prodrugs wherein the protein carrier comprises an amino acid sequence consisting of at least 100 amino acid residues forming random coil conformation and comprising alanine, serine and proline residues. It further relates to pharmaceutical compositions comprising said water-soluble protein carrier-linked prodrugs, their use as a medicament as well as methods of treatment and administration.
    Type: Application
    Filed: August 10, 2012
    Publication date: October 30, 2014
    Applicant: Ascendis Phama A/S
    Inventors: Ulrich Hersel, Dirk Vetter
  • Publication number: 20140315810
    Abstract: It is an object of the present invention to provide a new agent for the treatment of alopecia, the agent being not only effective and safe for, in particular, alopecia areata, androgenetic alopecia in a male, androgenetic alopecia in a female, female pattern alopecia, postpartum alopecia, seborrheic alopecia, alopecia pityroides, senile alopecia, cancer chemotherapy drug-induced alopecia, and alopecia due to radiation exposure, but also effective for a target having resistance to treatment with minoxidil or finasteride, there being no side effects such as an itching sensation, irritation, or feminization, and no contraindications, the agent suppressing dandruff or having a therapeutic effect for white hair, and the therapeutic effect for alopecia being maintained for a long period even when use of the agent is stopped.
    Type: Application
    Filed: April 17, 2014
    Publication date: October 23, 2014
    Applicants: IGISU Co., Ltd.
    Inventor: Kyoko Endo
  • Publication number: 20140287999
    Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.
    Type: Application
    Filed: March 18, 2014
    Publication date: September 25, 2014
    Applicant: Cardiorentis Ltd.
    Inventors: Veselin Mitrovic, Hartmut Luss, Wolf-Georg Forssmann, Markus Meyer, Klaus Dohler
  • Publication number: 20140274901
    Abstract: Materials and Methods related to using proANP to treat cardiorenal disease, including acute heart failure.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Tomoko Ichiki, John C. Burnett, JR.
  • Publication number: 20140255518
    Abstract: Compositions comprising a guanylyl cyclase C agonist in an amount effective to protect intestinal tissue against radiation or chemotherapy and methods of using such compositions to prevent GI syndrome in cancer patient undergoing radiation or chemotherapy and in individuals exposed to or susceptible to exposure to radiation are disclosed.
    Type: Application
    Filed: April 27, 2012
    Publication date: September 11, 2014
    Applicants: THOMAS JEFFERSON UNIVERSITY HOSPITALS, INC., THOMAS JEFFERSON UNIVERSITY
    Inventors: Peng Li, Scott A. Waldman, Evan Wuthrick
  • Publication number: 20140248269
    Abstract: Provided are a medicinal agent which is highly safe for use as the treatment of a malignant tumor and is capable of efficiently treating a malignant tumor, that is, a medicinal agent for treating a malignant tumor or for suppressing or preventing the exacerbation thereof, comprising at least one kind of natriuretic peptide receptor GC-A agonist and at least one kind of natriuretic peptide receptor GC-B agonist to be administered in combination; a therapeutic method comprising administering the agent; etc.
    Type: Application
    Filed: August 17, 2012
    Publication date: September 4, 2014
    Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, DAIICHI SANKYO COMPANY, LIMITED, OSAKA UNIVERSITY
    Inventors: Kenji Kangawa, Hiroshi Hosada, Takashi Nojiri, Meinoshin Okumura, Mayumi Furuya
  • Publication number: 20140243271
    Abstract: The problem to be solved by the present invention is to provide an effective and safe therapeutic preparation for rhinitis, which not only has significant effects on improvement in rhinitis, in particular allergic rhinitis, but also is rapid in manifestation of efficacy, fast-acting, and long-lasting, without local side effects. Means for solving the problem is a therapeutic preparation for rhinitis, in particular allergic rhinitis, comprising C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.
    Type: Application
    Filed: February 28, 2014
    Publication date: August 28, 2014
    Applicants: IGISU Co., Ltd.
    Inventor: Kyoko Endo
  • Patent number: 8815803
    Abstract: This invention provides a composition for increasing a body height of a patient with short stature or an individual other than patients with short stature. More specifically, the invention provides: a composition for increasing the body height of an individual comprising a guanyl cyclase B (GC-B) activator as an active ingredient, the composition being to be administered to an individual free from FGFR3 abnormality; a method for increasing the body height of an individual free from FGFR3 abnormality which comprises activating GC-B; a method for screening an agent for increasing the body height of an individual which comprises selecting an agent for increasing the body height using GC-B activity as an indication; and a method for extending a cartilage bone free from FGFR3 abnormality which comprises activating GC-B in an individual.
    Type: Grant
    Filed: March 31, 2005
    Date of Patent: August 26, 2014
    Inventors: Kazuwa Nakao, Akihiro Yasoda, Hidetomo Kitamura
  • Publication number: 20140228294
    Abstract: This document provides natriuretic polypeptides. For example, this document provides polypeptides having a natriuretic activity. In some cases, a polypeptide provided herein can have natriuretic activities without inducing excessive hypotension. This document also provides methods and materials for inducing natriuretic activities within a mammal.
    Type: Application
    Filed: April 21, 2014
    Publication date: August 14, 2014
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: John C. Burnett, JR., Candace Y.W. Lee
  • Patent number: 8802622
    Abstract: The invention provides a powdered composition for nasal administration, comprising a physiologically active peptide and cellulose acetate as the base, and having excellent nasal absorption for physiologically active peptides.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: August 12, 2014
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Masaru Matsumoto, Shuji Takeda, Kyohei Nobori
  • Publication number: 20140213520
    Abstract: Disclosed in certain embodiments is a method of treating a cardiovascular indication comprising administering a natriuretic peptide to a patient in need thereof within 24 hours of clinical assessment of the patient.
    Type: Application
    Filed: January 24, 2014
    Publication date: July 31, 2014
    Applicant: Cardiorentis Ltd.
    Inventor: JOHANNES HOLZMEISTER
  • Publication number: 20140213519
    Abstract: Disclosed is a method of treating a cardiovascular indication comprising administering a natriuretic peptide to a patient in need thereof within 24 hours of clinical assessment of the patient.
    Type: Application
    Filed: January 24, 2014
    Publication date: July 31, 2014
    Applicant: Cardiorentis Ltd.
    Inventor: JOHANNES HOLZMEISTER
  • Publication number: 20140179606
    Abstract: An agent for treating heart failure, which improves left ventricular diastolic function itself without depending on the diuretic effect or vasodilation effect; controls the pathological condition of diastolic functional failure; and prevents the recurrence, and can prevent dyspnea and death from the pathological condition, is provided. By directly acting on a heart, 4-[(2-{(2R)-2-[(1E,3S)-4-(4-fluorophenyl)-3-hydroxy-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}ethyl)thio]butanoic acid improves left ventricular diastolic function, and can effectively treat diastolic functional failure among heart failure types. Accordingly, by present invention, a new agent for treating heart failure that can relieve diastolic functional failure, for which no effective therapeutic method has been established, can be provided.
    Type: Application
    Filed: August 1, 2012
    Publication date: June 26, 2014
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshiya Kanaji, Kazuhiro Fuchibe, Masaya Takahashi
  • Publication number: 20140179605
    Abstract: This document provides natriuretic polypeptide delivery systems. For example, methods and materials related to natriuretic polypeptide delivery systems, methods and materials related to the use of such delivery systems to deliver natriuretic polypeptides to a mammal over a pro-longed period of time (e.g., weeks to months), and methods and materials related to treating heart failure conditions are provided.
    Type: Application
    Filed: March 7, 2013
    Publication date: June 26, 2014
    Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Horng H. Chen, John C. Burnett, JR.
  • Patent number: 8759317
    Abstract: A method of treating cancer through use of guanosine 3?,5?-cyclic monophosphate (cyclic GMP). Cyclic GMP decreases the number of human breast cancer and prostate adenocarcinoma as well as small-cell and squamous lung cells in culture by 30% (1 ?M), 84% (1 mM), 31% (1 ?M), and 30% (1 ?M), respectively. Cyclic GMP decreases DNA synthesis in human pancreatic, breast, and prostate adenocarcinomas as well as small-cell and squamous cell carcinomas of the lung at its 1 ?M concentration by 51%, 54%, 56%, 50% and 52%, respectively. Cyclic GMP when infused for one week decreases the tumor volume of human pancreatic adenocarcinomas in athymic mice 95% compared to untreated animals with human pancreatic adenocarcinomas.
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: June 24, 2014
    Assignee: University of South Florida
    Inventor: David L. Vesely
  • Publication number: 20140155315
    Abstract: The invention provides a synthetic polypeptide of Formula I? (SEQ ID NO: 1): X1-X2-X3-R—X5-X6-X7-X8-X9-X10-X11-X12-X13??I or an amide, an ester or a salt thereof, wherein X1, X2, X3, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia.
    Type: Application
    Filed: November 18, 2013
    Publication date: June 5, 2014
    Applicant: NOVARTIS AG
    Inventors: Frédéric Zecri, Kayo Yasoshima, Philipp Grosche, Jun Yuan, Hongjuan Zhao
  • Patent number: 8741842
    Abstract: This document provides natriuretic polypeptides. For example, this document provides polypeptides having a natriuretic activity. In some cases, a polypeptide provided herein can have natriuretic activities without inducing excessive hypotension. This document also provides methods and materials for inducing natriuretic activities within a mammal.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: June 3, 2014
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: John C. Burnett, Jr., Candace Y. W. Lee
  • Patent number: 8710006
    Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: April 29, 2014
    Assignee: Cardiopep Pharma GmbH
    Inventors: Veselin Mitrovic, Hartmut Luss, Wolf-Georg Forssmann, Markus Meyer, Klaus Dohler
  • Patent number: 8703704
    Abstract: A treatment method effective for promoting hair growth utilizes atrial natriuretic peptide.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: April 22, 2014
    Inventors: Masafumi Koide, Hisako Koide, Akio Iio
  • Patent number: 8691765
    Abstract: A method of stimulating neuronal growth or repair comprising exposing a target neuron or neuronal area to a solution of the metallothionein isoform MT-IIA.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: April 8, 2014
    Assignee: University of Tasmania
    Inventors: Adrian Keith West, Meng Inn Chuah, James Clement Vickers, Roger Steven Chung
  • Publication number: 20140072557
    Abstract: A medicinal agent for suppressing or preventing the metastasis of a malignant tumor, the agent comprising, as an active ingredient, at least one kind of vascular endothelial intracellular cGMP enhancer.
    Type: Application
    Filed: February 27, 2012
    Publication date: March 13, 2014
    Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, DAIICHI SANKYO COMPANY, LIMITED, OSAKA UNIVERSITY
    Inventors: Kenji Kangawa, Hiroshi Hosada, Takashi Nojiri, Meinoshin Okumura
  • Publication number: 20140072520
    Abstract: The problem to be solved by the present invention is to provide a safe and efficacious therapeutic agent for dermatitis which is not only safe and efficacious for patients with dermatitis, in particular atopic dermatitis, but also significantly effective for severe cases that are judged to be intractable by conventional external preparations, and which is also safely applicable to affected areas such as the face and neck, as well as to subjects with sensitive skin, such as infants and females. Furthermore, the invention aims to provide an external preparation that is efficacious as skin care cosmetics having effects to improve elasticity and wrinkles of the skin, moisturizing effects, and hair-growth effects. The means for solving the problem is a skin external-preparation composition, in particular, a therapeutic agent for dermatitis or a skin texture-improving agent, having C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.
    Type: Application
    Filed: September 3, 2013
    Publication date: March 13, 2014
    Applicant: IGISU Co., Ltd.
    Inventor: Kyoko ENDO
  • Publication number: 20140066881
    Abstract: The invention provides methods of improving circulation in a subject undergoing a cardiac resuscitation protocol, reducing the risk of stroke in a subject undergoing a cardiac resuscitation protocol, improving the efficacy of cardiac resuscitation in a subject undergoing a cardiac resuscitation protocol, and providing cardiac resuscitation to a subject having cardiac arrest. Also provided are kits including a composition containing at least one vasoconstrictor formulated for systemic administration, and a composition containing at least one vasodilator formulated for nasal administration.
    Type: Application
    Filed: March 13, 2013
    Publication date: March 6, 2014
    Applicant: ZOLL MEDICAL CORPORATION
    Inventor: Gary A. Freeman
  • Publication number: 20140066367
    Abstract: This document provides methods and material related to natriuretic polypeptides. For example, substantially pure polypeptides having a natriuretic peptide activity, nucleic acids encoding polypeptides having a natriuretic peptide activity, host cells containing such nucleic acids, and methods for inducing a natriuretic or diuretic activity within a mammal are provided.
    Type: Application
    Filed: March 12, 2013
    Publication date: March 6, 2014
    Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Horng H. Chen, John C. Burnett, JR., Daniel J. McCormick
  • Patent number: 8642550
    Abstract: This document provides natriuretic polypeptides. For example, this document provides polypeptides having a natriuretic activity. In some cases, a polypeptide provided herein can have natriuretic activities without lowering blood pressure. Methods and materials for inducing natriuretic activities within a mammal also are provided.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: February 4, 2014
    Assignees: Mayo Foundation for Medical Education and Research, Regents of the University of Minnesota
    Inventors: Deborah Dickey, John C. Burnett, Jr., Lincoln R. Potter
  • Publication number: 20140031291
    Abstract: Disclosed herein are methods for the diagnosis, detection, and treatment of cardiovascular disease and symptoms thereof in a subject. Disclosed herein are methods of diagnosing ischemic heart disease, non-ischemic heart disease, myocardial infarction, tachy-pacing induced non-ischemic heart disease, heart failure, and catecholaminergic-induced arrhythmia and symptoms thereof in a subject. Disclosed herein are methods of screening the efficacy of a pharmaceutical agent for treating cardiovascular disease and symptoms thereof in a subject.
    Type: Application
    Filed: July 18, 2013
    Publication date: January 30, 2014
    Applicant: THE OHIO STATE UNIVERSITY
    Inventors: Peter Mohler, Cynthia Carnes, Chenglong Li, Thomas Hund, Pui-Kai Li
  • Publication number: 20140030336
    Abstract: A pharmaceutical composition for the treatment or acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.
    Type: Application
    Filed: July 30, 2013
    Publication date: January 30, 2014
    Applicant: Orexo AB
    Inventors: Anders Pettersson, Christer Nystrom
  • Patent number: 8637462
    Abstract: This document relates to methods and materials for treating diseases or disorders associated with elevated platelet counts (e.g., essential thrombocythemia, secondary thrombocytosis, congenital amegakaryocytic thrombocytopenia, sepsis, or asplenism) as well as methods and materials for treating diseases or disorders associated with elevated platelet adhesion to collagen (e.g., acute coronary syndromes, angina pectoris, chronic atherosclerosis, diabetes, or hypertension).
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: January 28, 2014
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Robert D. Simari, Sinny Delacroix
  • Publication number: 20130345136
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Application
    Filed: August 28, 2013
    Publication date: December 26, 2013
    Applicant: Alcon Research, Ltd.
    Inventors: Mark R. Hellberg, Iok-Hou Pang
  • Publication number: 20130345135
    Abstract: The present invention provides for methods of treating and slowing the onset of heart failure. The inventors have determined that myosin binding to unphosphorylated Myosin Binding Protein C (MyBP-C) plays a key role in the diminution of cardiac contractile force and frequency in heart failure. The present invention provides peptide inhibitors of the MyBP-C/myosin interaction, thereby increasing both cardiac contractile force and frequency in the failing heart, as well as in patients not yet exhibiting frank heart failure.
    Type: Application
    Filed: March 14, 2013
    Publication date: December 26, 2013
    Inventors: RICHARD L. MOSS, Ariel Fernandez
  • Publication number: 20130330366
    Abstract: In one aspect, the invention relates to compounds having the formula XII: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Application
    Filed: June 6, 2013
    Publication date: December 12, 2013
    Inventors: Adam D. Hughes, Melissa Fleury
  • Publication number: 20130330365
    Abstract: In one aspect, the invention relates to compounds having the formula X: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Application
    Filed: June 6, 2013
    Publication date: December 12, 2013
    Inventors: Adam D. Hughes, Melissa Fleury
  • Publication number: 20130323244
    Abstract: The present invention provides methods, compositions, and kits for the treatment of neurocutaneous syndromes, such as neurofibromatosis type I; disorders associated with overactivation of FGFR3, such as achondroplasia; bone or cartilage disorders; or vascular smooth muscle disorders; or for the elongation of bone. In some embodiments, the present invention provides polypeptides having an alkaline phosphatase peptide fused to an Fc domain of an immunoglobulin or a natriuretic peptide fused to an Fc domain of an immunoglobulin. Such polypeptides can be administered to subjects, e.g., subcutaneously, to treat a neurocutaneous syndrome, a disorder associated with overactivation of FGFR3, a bone or cartilage disorder, or a vascular smooth muscle disorder, or to elongate bone.
    Type: Application
    Filed: May 21, 2013
    Publication date: December 5, 2013
    Applicants: Vanderbilt University, Alexion Pharma International Sarl
    Inventors: Philippe CRINE, Florent Elefteriou
  • Patent number: 8598121
    Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: December 3, 2013
    Assignee: Biomarin Pharmaceutical Inc.
    Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel Claude Vellard, Augustus O. Okhamafe
  • Patent number: 8586536
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: November 19, 2013
    Assignee: Theravance, Inc.
    Inventors: Roland Gendron, Melissa Fleury, Adam D. Hughes